RE-BVS – Piemonte Repository

Sfoglia per AUTORE
NICOLARDI L
Collezione AO Ordine Mauriziano

Items : 5

Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study. in The oncologist / Oncologist. 2022 Sep 2;27(9):e723-e730. doi: 10.1093/oncolo/oyac129.

2022
AO Ordine Mauriziano

Mentrasti G; Cantini L; Zichi C; D'Ostilio N; Gelsomino F; Martinelli E; Chiari R; La Verde N; Bisonni R; Cognigni V; Pinterpe G; Pecci F; Migliore A; Aimar G; De Vita F; Traisci D; Spallanzani A; Martini G; Nicolardi L; Cona MS; Baleani MG; Rocchi MLB; Berardi R;

Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406]. in ESMO open / ESMO Open. 2022 Apr;7(2):100471. doi: 10.1016/j.esmoop.2022.100471. Epub 2022 Apr 1.

2022
AO Ordine Mauriziano

Cantini L; Mentrasti G; Lo Russo G; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; La Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; et alii...

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. in ESMO open / ESMO Open. 2022 Apr;7(2):100406. doi: 10.1016/j.esmoop.2022.100406. Epub 2022 Feb 3.

2022
AO Ordine Mauriziano

Cantini L; Mentrasti G; Russo GL; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; et alii...

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2022 Apr;71(4):865-874. doi: 10.1007/s00262-021-03045-9. Epub 2021 Aug 31

2022
AO Ordine Mauriziano

Marconcini R; Intagliata S; Audisio M; Lai E; Aprile G; Buti S; Ghidini M; Macrini S; Inno A; Di Marino P; Tuzi A; Nicolardi L; Occhipinti MA; Pergolesi F; Veltri E; Adamo V; Filetti M; Ficorella C; Pantano F; Citarella F; Falcone A; Bossi P; Di Maio M; Scartozzi M; Di Noia V; Calvetti L; Bersanelli M; Grossi F; Gori S; et alii...

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. in Journal of clinical medicine / J Clin Med. 2021 Mar 2;10(5):1005. doi: 10.3390/jcm10051005.

2021
AO Ordine Mauriziano

Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; Rinaldi S; Nicolardi L; Caglio A; Aerts S; Cortellini A; Ficorella C; Chiari R; Di Maio M; Dingemans AC; Aerts JGJV; Berardi R; Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; et alii...